On March 1, 2021 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that it will participate in the following investor conferences in the month of March, with presentations led by the Company’s President and Chief Exeutive Officer, Rodney Varner (Press release, Genprex, MAR 1, 2021, View Source [SID1234575832]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sachs 14th Annual European Life Sciences CEO Forum (Virtual)

Date: March 10-12, 2021

Time: On demand, starting at 10 a.m. Central European Time (CET) on Wednesday, March 10

Registration Link: http://bit.ly/3pRX0FG

33rd Annual Roth Conference (Virtual)

Date: March 15-17, 2021

Time: On demand, starting at 9 a.m. Eastern Standard Time (EST) on Monday, March 15

Registration Link: http://bit.ly/3srur3N

The Company invites investors to join the webcast presentations, and Mr. Varner will be available for one-on-one meetings with investors throughout the conferences. The presentations will be available for replay on the Company’s website (www.genprex.com) for a period of time following the conferences.